41,077 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Bought by Monimus Capital Management LP

Monimus Capital Management LP bought a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 41,077 shares of the company's stock, valued at approximately $1,127,000.

Other large investors have also made changes to their positions in the company. Steward Partners Investment Advisory LLC lifted its position in BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock valued at $28,000 after purchasing an additional 472 shares during the period. Advisors Asset Management Inc. lifted its holdings in BridgeBio Pharma by 56.1% in the third quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company's stock valued at $117,000 after buying an additional 1,645 shares during the period. Avanza Fonder AB bought a new position in BridgeBio Pharma in the fourth quarter valued at approximately $181,000. First Bank & Trust acquired a new stake in BridgeBio Pharma during the 4th quarter worth $205,000. Finally, Moss Adams Wealth Advisors LLC bought a new stake in shares of BridgeBio Pharma during the 4th quarter valued at $208,000. Institutional investors and hedge funds own 99.85% of the company's stock.

BridgeBio Pharma Stock Down 2.5 %

Shares of NASDAQ:BBIO traded down $0.82 during midday trading on Tuesday, reaching $32.19. 1,942,133 shares of the company were exchanged, compared to its average volume of 2,111,078. The firm has a market cap of $6.12 billion, a PE ratio of -11.29 and a beta of 1.07. BridgeBio Pharma, Inc. has a fifty-two week low of $21.62 and a fifty-two week high of $39.47. The stock has a fifty day simple moving average of $33.79 and a two-hundred day simple moving average of $28.97.

Remove Ads

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million during the quarter, compared to analysts' expectations of $4.04 million. As a group, analysts forecast that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

Insiders Place Their Bets

In related news, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of BridgeBio Pharma stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $32.96, for a total transaction of $197,760,000.00. Following the completion of the sale, the insider now owns 19,260,971 shares of the company's stock, valued at approximately $634,841,604.16. The trade was a 23.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Global Investors Lp Viking sold 3,065,616 shares of BridgeBio Pharma stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $34.90, for a total transaction of $106,989,998.40. Following the completion of the sale, the insider now owns 22,055,375 shares of the company's stock, valued at $769,732,587.50. This trade represents a 12.20 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 9,579,739 shares of company stock valued at $323,171,901 in the last quarter. 24.66% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

BBIO has been the topic of several recent research reports. HC Wainwright restated a "buy" rating and issued a $49.00 price target on shares of BridgeBio Pharma in a research report on Thursday, February 13th. Evercore ISI boosted their target price on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a research report on Monday, December 23rd. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $95.00 price target on shares of BridgeBio Pharma in a research note on Friday, February 21st. Scotiabank lifted their price objective on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Friday, February 21st. Finally, Citigroup upped their target price on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the company a "buy" rating in a research note on Friday, February 21st. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $51.55.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.